SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an ...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first ...
Data can often feel overwhelming—rows upon rows of numbers, scattered information, and endless spreadsheets that seem to blur together. If you’ve ever stared at a dataset wondering how to make sense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback